B Group, Inc.
Long book
$134.9M
Q1 2026
Positions
20
Top-10 weight
81%
concentration
Last quarter
+18.9%
SPY +14.8%
Turnover
25%
of book per quarter
Strategy in plain words
auto-generated from filingsB Group, Inc. is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $134.9M US long book across 20 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: ADMA BIOLOGICS INC, PALISADE BIO INC, PRAXIS PRECISION MEDICINES I, CELLECTIS - ADR, ZAI LAB LTD-ADR.
Over the last 6 quarters its long book ran on average 1.9pp per quarter ahead of the S&P 500, beating the index in 3 of 6 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
+3.4%
Q1 2025
+5.4%
Q2 2025
+5.6%
Q3 2025
+30.2%
Q4 2025
-24.6%
Q1 2026
+18.9%
Sector allocation
Healthcare 100%
Other 0%
Long book by quarter
What does B Group, own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ADMA ADMA BIOLOGICS INC | Healthcare | 3.2M | $28.9M | 21.4% | +30.5% |
| PALI PALISADE BIO INC | Healthcare | 11.4M | $20.0M | 14.8% | +153.7% |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 33.2K | $10.7M | 7.9% | Held |
| TSHA TAYSHA GENE THERAPIES INC | Healthcare | 1.8M | $8.0M | 6.0% | Held |
| NRXP NRX PHARMACEUTICALS INC | Healthcare | 3.0M | $6.4M | 4.7% | New |
| IOVA IOVANCE BIOTHERAPEUTICS INC | Healthcare | 1.5M | $5.3M | 3.9% | Held |
| SYRE SPYRE THERAPEUTICS INC | Healthcare | 100.0K | $5.0M | 3.7% | Held |
| DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 67.5K | $4.9M | 3.7% | New |
| ASMB ASSEMBLY BIOSCIENCES INC | Healthcare | 175.7K | $4.9M | 3.6% | Held |
| AURA AURA BIOSCIENCES INC | Healthcare | 597.6K | $4.0M | 3.0% | +4.4% |
| ORKA ORUKA THERAPEUTICS INC | Healthcare | 75.0K | $3.7M | 2.7% | Held |
| SGHT SIGHT SCIENCES INC | Healthcare | 970.0K | $3.7M | 2.7% | +5.4% |
| RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 135.0K | $2.8M | 2.1% | Held |
| APGE APOGEE THERAPEUTICS INC | Healthcare | 7.5K | $631K | 0.5% | -62.5% |
| FHTX FOGHORN THERAPEUTICS INC | Healthcare | 102.0K | $488K | 0.4% | New |
| SLNOEUR SOLENO THERAPEUTICS INC | — | 7.5K | $251K | 0.2% | New |
| REPL REPLIMUNE GROUP INC | Healthcare | 26.0K | $199K | 0.1% | New |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 20 | $134.9M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 16 | $135.4M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 20 | $135.9M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 17 | $129.9M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 19 | $116.7M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 18 | $163.6M | canonical | SEC ↗ |